Journals / art / 2014 / Cilt: 29 - Sayı: 2

Clinical manifestations of neuropsychiatric systemic lupus erythematosus in chinese patients

Journal
art
Pages
88–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These patients can be effectively treated with corticosteroids and immunosuppressants.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to describe the clinical manifestations, laboratory abnormalities, and therapeutic responses of neuropsychiatric systemic lupus erythematosus (NPSLE) among Chinese population.
📊
Key Findings & Data:Patients and methods: We retrospectively reviewed the medical records of 1,772 patients, who suffered from systemic lupus erythematosus (SLE) admitted to the Department of Rheumatology of Shanghai Renji Hospital between January 1999 and December 2011.
💡
Conclusion & Impact:These patients can be effectively treated with corticosteroids and immunosuppressants.
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to describe the clinical manifestations, laboratory abnormalities, and therapeutic responses of neuropsychiatric systemic lupus erythematosus (NPSLE) among Chinese population. Patients and methods: We retrospectively reviewed the medical records of 1,772 patients, who suffered from systemic lupus erythematosus (SLE) admitted to the Department of Rheumatology of Shanghai Renji Hospital between January 1999 and December 2011. Seventy-six patients were diagnosed with NPSLE. Demographic characteristics of the patients and clinical manifestations were analyzed and laboratory abnormalities were recorded. Results: These patients had not only common SLE symptoms, but also 14 types of neuropsychiatric (NP) presentations. Proteinuria (61%), fever (55%), and infection (47%) were frequent SLE-related symptoms, while seizure (47%), delirium (26%), and headache (18%) were frequently seen NP presentations. These patients also presented abnormal laboratory tests, including positive antinuclear antibodies (78%), low levels of serum complement-3 (76%), abnormal erythrocyte sedimentation rate (68%), and higher levels of serum immunoglobulin G (59%) as well as abnormal cranial magnetic resonance imaging findings (58%). Following treatment with corticosteroids, immunosuppressants, anti-epileptics, and anti- psychotics, 53 patients survived and most of them had no NP-related sequels. Conclusion: Patients with NPSLE may display various clinical manifestations and laboratory abnormalities. These patients can be effectively treated with corticosteroids and immunosuppressants.

🔖

Cite This Article

FAN, W., ZHOU, Z., LU, L., CHEN, S., BAO, C. (2014). Clinical manifestations of neuropsychiatric systemic lupus erythematosus in chinese patients. art, Cilt: 29 - Sayı: 2, 88–93. https://ajindex.com/articles/200492

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003;12:935–42
  2. Kajs-Wyllie M. Lupus cerebritis: a case study. J Neurosci Nurs 2002;34:176–83
  3. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis oneuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:529–35
  4. Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero JBae SC, Gordon C, et al. Short-term outcome oneuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohorstudy. Arthritis Rheum 2008;59:721–9
  5. Jönsen A, Bengtsson AA, Nived O, Ryberg BSturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish populationincreased morbidity but low mortality. Rheumatology (Oxford) 2002;41:1308–12
  6. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633–43
  7. Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 2006;15:835–9
  8. Lu X, Gu Y, Wang Y, Chen S, Ye S. Prognostic factors of lupus myelopathy. Lupus 2008;17:323–8
  9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
  10. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004;31:2156–62
  11. Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 2005;4:329–44
  12. Stojanovich L, Zandman-Goddard G, Pavlovich S, Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 2007;6:421–6
  13. Zhou HQ, Zhang FC, Tian XP, Leng XM, Lu JJ, Zhao Y, et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 2008;17:93–9
  14. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608
  15. Hanly JG. Neuropsychiatric lupus. Curr Rheumatol Rep 2001;3:205–12
  16. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a l